Working groups
Adam is a molecular biologist and biochemist. During his PhD, he investigated the Mycobacterium species and characterised the Pup-Proteasome system that is crucial for pathogenic mycobacteria to survive hostile environments inside macrophages and persist inside the host.
Shortly after his PhD, Adam joined the pharmaceutical industry as a scientist at CSL’s Recombinant and Gene Product Development group where he gained valuable experience in various pharmaceutical products development, large scale manufacturing, quality control and quality assurance.
After a few years at CSL, Adam joined St Vincent’s Institute of Medical Research working on an oncology-focused project with Pfizer’s Centres of Therapeutic Innovation. This collaboration aimed to identify potential new small molecules that target the DNA damage response, which is common to most cancers.
After completing the Pfizer project, Adam joined La Trobe University working in research administration, specifically reporting on realised research impact beyond academia. He ensured La Trobe University’s continuous success in the Times Higher Education Impact ranking by aligning its operations and outputs with the United Nations Sustainable Development Goals (SDGs).
Adam is currently a senior research officer at Burnet working on malaria vaccines development as part of the Burnet Vaccine Initiative, while also serving as the President of the Students and Early Career Professional group at the Parenteral Drug Association in Australia (PDA Australia Chapter).
The Optimise Study has followed a cohort of around 700 Victorians since September 2020. A rapid survey was conducted between 4 and 14 March 2022 to assess Optimise participants' concerns about children returning to school, COVID-19 testing in schools, views about COVID-19 prevention measures taken in schools, and the acceptability of closing schools under certain circumstances.
The Optimise Study: A rapid survey examining concerns about children returning to school in 2022. (PUBLIC HEALTH REPORT)bioRxiv (Cold Spring Harbor Laboratory)
Ashley Lisboa-Pinto, Jo-Anne Chan, Shirley Lu, Alex C. Harris, Adam Thomas, D. Herbert Opi, Linda Reiling, Leanne J. Robinson, James G. Beeson, Jo-Anne Chan
bioRxiv (Cold Spring Harbor Laboratory)
Ashley Lisboa-Pinto, Jo-Anne Chan, Shirley Lu, Alex C. Harris, Adam Thomas, D. Herbert Opi, Linda Reiling, Leanne J. Robinson, James G. Beeson, Jo-Anne Chan
Vaccination is a highly effective strategy to protect populations against infectious diseases. Highly protective and long-lasting vaccines are needed to reduce the global burden of malaria and enable elimination.
We're developing novel solutions and high-quality evidence to inform policies and practices that address the major barriers in malaria elimination.
The program brings together experts to achieve the goals of malaria elimination in the Asia-Pacific region and globally.